This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Brand Strength to Aid Colgate (CL) Despite High Inflation
by Zacks Equity Research
Despite rising raw material costs, Colgate's (CL) robust innovation and expansion plans are likely to drive growth in the long term.
Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FVD
Why Is Clorox (CLX) Up 5.9% Since Last Earnings Report?
by Zacks Equity Research
Clorox (CLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
Beat the Market the Zacks Way: Walt Disney (DIS), AmerisourceBergen (ABC), C.H. Robinson Worldwide (CHRW) in Focus
by Tirthankar Chakraborty
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
Taiwan Semiconductor Manufacturing and The Clorox Company have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Taiwan Semiconductor Manufacturing and The Clorox Company are part of Zacks Bull and Bear of the Day article.
Bear of the Day: The Clorox Company (CLX)
by Derek Lewis
Overwhelmingly negative estimate revisions paint a grim picture for the company in the short term.
Clorox (CLX) Falls on Q4 Earnings & Sales Miss, Bleak View
by Zacks Equity Research
Clorox's (CLX) Q4 results reflect the impacts of lower shipments, higher tax rate and continued costs headwinds related to elevated manufacturing and logistics costs, and higher commodity costs.
Clorox (CLX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of -2.11% and 2.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Clorox (CLX) Readies for Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Clorox's (CLX) fourth-quarter fiscal 2022 results are likely to reflect gains from the IGNITE strategy and pricing actions, whereas elevated cost concerns are likely to have affected profits.
Procter & Gamble (PG) Q4 Earnings Miss Estimates
by Zacks Equity Research
P&G (PG) delivered earnings and revenue surprises of -1.63% and 0.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Clorox (CLX) Q4 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Clorox (CLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clorox (CLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed at $147.77 in the latest trading session, marking a -0.05% move from the prior day.
The Zacks Analyst Blog Highlights AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale
by Zacks Equity Research
AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale have been included in this Analyst Blog.
Beat the Market Like Zacks: AMN Healthcare, Boeing, Clorox, Home Depot in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
Solid Demand & Innovation Aid Clorox (CLX) Amid Inflation Woes
by Zacks Equity Research
Clorox (CLX) is likely to gain from a robust product demand, brand strength and innovation. Its cost-saving efforts bode well amid ongoing inflationary pressures.
Clorox (CLX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed the most recent trading day at $140.75, moving +0.46% from the previous trading session.
Clorox (CLX) Moves 5.2% Higher: Will This Strength Last?
by Zacks Equity Research
Clorox (CLX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Clorox (CLX) Stock Moves -0.45%: What You Should Know
by Zacks Equity Research
In the latest trading session, Clorox (CLX) closed at $122.57, marking a -0.45% move from the previous day.
Clorox (CLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Clorox (CLX) closed at $134.33, marking a +0.04% move from the previous day.
Clorox (CLX) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clorox (CLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clorox (CLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Elevated manufacturing and logistics costs might have hurt Clorox's (CLX) bottom line in third-quarter fiscal 2022. Nonetheless, its IGNITE strategy appears encouraging.
Stock Market News for May 4, 2022
by Zacks Equity Research
Wall Street closed higher on Tuesday after a volatile session.
Clorox (CLX) Q3 Earnings & Sales Beat on Solid Demand
by Zacks Equity Research
Clorox (CLX) Q3 results gained from solid demand, pricing actions and cost savings efforts. However, the ongoing inflationary pressures led to lowered bottom line view for fiscal 2022.
The Zacks Analyst Blog Highlights Avis Budget, NXP Semi, Clorox, MGM Resorts and Expedia
by Zacks Equity Research
Avis Budget, NXP Semi, Clorox, MGM Resorts and Expedia have been included in this Analyst Blog.